EMA Authorised: Imaavy (nipocalimab) — Janssen Cilag International NV

View source ↗

Summary

EMA has authorised Imaavy (nipocalimab) for myasthenia gravis, with Janssen Cilag International NV as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• IMAAVY (NIPOCALIMAB)

Snippet

Status: Authorised. Therapeutic area: Myasthenia Gravis. MAH: Janssen Cilag International NV. Decision date: 23/07/2026